http://biz.yahoo.com/rf/990526/nl.html
SIBIA, Lilly in research pact
LA JOLLA, Calif., May 26 (Reuters) - SIBIA Neurosciences Inc. and Eli
Lilly and Co. have entered into a three-year pact to collaborate in
developing compounds effective in treating central nervous system
disorders, SIBIA said Wednesday.
<SNIP>
Lilly will conduct and fund all clinical trials for compounds discovered
during the project and will receive an exclusive option to SIBIA's two
clinical candidates, SIB-1508Y for Parkinson's disease and SIB-1553A for
Alzheimer's disease, both currently in phase II trials.
SIBIA and Lilly will work together to identify and optimize compounds
selective for subtypes of nicotinic acetylcholine receptors (nAChRs).
``A growing body of evidence suggests that regulation of specific nAChR
subtypes may allow therapeutic intervention in a number of disorders
including pain, schizophrenia, depression, Alzheimer's disease and
Parkinson's disease,'' said Jeffrey McKelvy, chief scientific officer of
SIBIA. "We believe that the nAChRs are a rich area for drug discovery.
``With the combination of the resource commitment from Lilly and the
expertise that each company brings to the collaboration, we anticipate
that this joint effort could produce a number of drug candidates for
neurological and psychiatric disorders.''
Copyright © 1999 Reuters Limited.
--
Judith Richards, London, Ontario, Canada
<[log in to unmask]>
^^^
\ /
\ | / Today’s Research
\\ | // ...Tomorrow’s Cure
\ | /
\|/
```````
